Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Oral Rigosertib in Patients With Relapsed or Metastatic, Platinum-resistant, Human Papillomavirus Positive or Negative Squamous Cell Carcinoma

NCT01807546 is registered in ClinicalTrials.gov with Traws Pharma, Inc. as lead sponsor.

NCT NCT01807546
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01807546 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Oral Rigosertib in Patients With Relapsed or Metastatic, Platinum-resistant, Human Papillomavirus Positive or Negative Squamous Cell Carcinoma
Lead sponsor
Traws Pharma, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2013
Completion date
April 30, 2016
Enrollment
64 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

anal squamous cell carcinoma, cervical squamous cell carcinoma, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, lung squamous cell carcinoma, penile squamous cell carcinoma, skin squamous cell carcinoma